functional carcinoid tumour
Endocrinology · 2022–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanreotide Initiation of treatment for acromegaly, functional carcinoid tumour, and non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET) in the community… | Jul 2024 | Recommended with restriction | 3 individuals |
| lanreotide Treatment of acromegaly, functional carcinoid tumour, and gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally… | Nov 2022 | Recommended with restriction | input received NeuroEndocrine Cancer Australia |
Who spoke
NeuroEndocrine Cancer Australia
What the PBS pays
$81M in government benefit over 2024–25, across 37,496 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lanreotide | $40.7M |
| lanreotide acetate | $40.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.